Strattera Dosing for 122.6 lb Patient
For a patient weighing 122.6 lb (55.6 kg), 18 mg of Strattera is significantly below the recommended therapeutic dose and should be increased to approximately 67 mg/day as the initial target dose (1.2 mg/kg/day), with potential titration up to 83 mg/day (1.5 mg/kg/day) based on clinical response.
Weight-Based Dosing Algorithm
The FDA label and clinical trials establish clear weight-based dosing for atomoxetine 1:
- Initial target dose: 1.2 mg/kg/day (approximately 67 mg for this 55.6 kg patient)
- Maximum recommended dose: 1.8 mg/kg/day (approximately 100 mg for this patient)
- Absolute maximum: 100 mg/day for children/adolescents
Evidence for Optimal Dosing
The dose-response relationship is well-established. In pivotal trials, 1.2 mg/kg/day and 1.8 mg/kg/day showed statistically significant superiority over placebo, while 0.5 mg/kg/day (approximately 28 mg for this patient) was not superior to placebo 1, 2. The current dose of 18 mg represents only 0.32 mg/kg/day—well below even the ineffective 0.5 mg/kg/day threshold.
A 2024 dose-response meta-analysis of 2,250 patients confirmed that efficacy increases up to 1.4 mg/kg/day, after which it plateaus 3. This supports targeting 1.2-1.4 mg/kg/day as the optimal therapeutic range.
Titration Strategy to Minimize Side Effects
To reduce early adverse events, use slow titration over 1-2 weeks with twice-daily dosing:
- Start at approximately 0.5 mg/kg/day (28 mg) divided twice daily
- Increase to target dose of 1.2 mg/kg/day (67 mg) over 7-14 days
- Consider once-daily morning dosing after tolerability established
Evidence shows that slow titration with twice-daily dosing significantly reduces somnolence (4.2% vs 14.3%) and decreased appetite (8.0% vs 14.3%) compared to rapid titration 4. Fast titration to target dose over 3 days increases early discontinuation risk without improving long-term outcomes.
Monitoring Requirements
Before increasing the dose, obtain:
- Personal and family cardiac history (sudden death, arrhythmias, cardiomyopathy, long QT syndrome)
- Baseline heart rate and blood pressure
- Consider ECG if any cardiac risk factors present 5
Monitor for the FDA black box warning regarding increased suicidal ideation, particularly during dose escalation 5.
Clinical Pitfalls
- Underdosing is common: The current 18 mg dose falls far below the evidence-based therapeutic range and is unlikely to provide meaningful ADHD symptom control
- Premature discontinuation: Gastrointestinal symptoms and somnolence are transient and typically resolve with slower titration 6
- Expecting immediate response: Unlike stimulants, atomoxetine requires 4-6 weeks at therapeutic doses to achieve full effect 1
The Asian guidelines confirm similar dosing, with maximum doses of 100-120 mg/day and weight-based titration strategies 7.